About Axio Biosolutions
Axio is a MedTech R&D and Manufacturing Company focused on Advanced Surgical and Wound Care. Axio has the distinction of being the first company from India to get USFDA clearance for a Wound Care/Hemostat product. Controlling life-threatening bleeding continues to be the major cause of death from traumatic injuries. Axiostat is its flagship product developed to reduce mortality due to traumatic bleeding. A CE approved product, Axiostat is based on a patented novel 100% chitosan platform and has variants catering to Emergency & Trauma, Military, Cardiovascular, and Dental applications.
Open positions (1)
Company details
Funding
Total raised
$20.5M
Last stage
Series B
Investors
Founders
Leo Mavely
Co-founded Axio Biosolutions in 2008 after incubation at NirmaLabs, Ahmedabad. Bioengineering undergraduate who led the development of Axiostat, India's first USFDA-cleared wound care/hemostat product.
LinkedInAshish Pandya
Co-founded Axio Biosolutions alongside Leo Mavely; worked on developing hemostatic wound care solutions at NirmaLabs incubator.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.